Davide Bertoldo studied Pharmaceutical Biotechnology at the University of Padova (Italy) and University of Liège (Belgium). In 2012, he joined the Laboratory of Therapeutic Proteins and Peptides at EPFL (Switzerland). During his PhD, he developed peptide macrocycles targeting a variety of proteins, including β-catenin and actin. In 2017, he joined the Large Molecule Research unit of Roche pRED in Penzberg (Munich area, Germany) where he is part of a team engaged in creating innovative bispecific antibodies for therapeutic applications. He is specialized in phage display and antibody engineering.